Klin Farmakol Farm. 2005;19(3):169-173

Combination therapy for hypertension

Milan Grundmann, Ivana Kacířová
Ústav klinické farmakologie FNsP a ZSF Ostravské univerzity, Ostrava

Current outcomes of antihypertensive therapy remain unsatisfactory since only one in four patients are treated adequately. Most patients with diabetes, stroke and in elderly achieve good compensation of hypertension only using combination therapy. The most commonly used double combinations include diuretics + betalytics, diuretics + ACEI, diuretics + AT1 blockers, and ACEI + calcium channel blockers. Additional options of combination therapy are highlighted in this review. The evidence for double combination use according to evidence based medicine remains inadequate, while for triple combination use there is none. Triple combination drugs are selected based on clinical pharmacology knowledge of their various mechanisms. If triple-combination antihypertensive therapy is unsuccessful, the hypertension is referred to as pharmacoresistant hypertension in which the absence of a diuretic in combination is, however, the commonest mistake.

Keywords: Key words: hypertension, combination therapy, EBM and combination therapy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grundmann M, Kacířová I. Combination therapy for hypertension. Klin Farmakol Farm. 2005;19(3):169-173.
Download citation

References

  1. Mensah GA. The global burden of hypertension: good news and bad news. Cardiol Clin. 2002; 20: 181-185. Go to original source... Go to PubMed...
  2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206. Go to original source... Go to PubMed...
  3. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572. Go to original source... Go to PubMed...
  4. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21: 1011-1053.
  5. Cífková R, Horký K, Widimský J sr, Widimský J jr, Filipovský J, Grundmann M, Monhart V, Rosolová H, Souček M, Špinar J, Vítovec J. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lékařství, 50, 2004; 9: 709-722.
  6. Weber M. Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? Eur Heart J. 2003; 5 (suppl C): C1-C4. Go to original source...
  7. Moser M, Prisant LM. Low-dose combination therapy in hypertension. Am Fam Physician. 1997; 56 (5): 1275-1276, 1279, 1282. Go to PubMed...
  8. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press. 2003; (suppl 1): 36-43. Go to original source... Go to PubMed...
  9. Oparil S, Aurup P, Snavely D, et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol. 2001; 87: 721-726. Go to original source... Go to PubMed...
  10. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
  11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-1762. Go to original source... Go to PubMed...
  12. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther. 2003; 1: 43-50. Go to original source... Go to PubMed...
  13. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999; 21: 973-985. Go to original source... Go to PubMed...
  14. Volpe M. Hypertension therapy: mixing, matching and meeting targets. Adv Ther. 2004; 21: 107-122. Go to original source... Go to PubMed...
  15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317: 703-713.
  16. Black HR, Elliott WJ, Neaton JD, et al. Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension. 2001; 37: 12-18. Go to original source... Go to PubMed...
  17. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805-2816. Go to original source... Go to PubMed...
  18. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens. 2000; 18: 327-337. Go to original source... Go to PubMed...
  19. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967; 202: 1028-1034. Go to PubMed...
  20. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041.
  21. Dählof B, Lindholm LH, et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991; 338: 1281-1285. Go to original source... Go to PubMed...
  22. Medical Research Council Working Party. MRC Trial of treatment of mild hypertension. BMJ 1985; 291: 47-104. Go to original source...
  23. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003. Go to original source... Go to PubMed...
  24. Kjeldsen SE, Dahlöf B. Devereux RB, et al. For the Losartan intervention for Endpoint reduction (LIFE) study group. Benefits of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a LIFE substudy. JAMA. 2002; 288: 1491-1498. Go to original source... Go to PubMed...
  25. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875-886. Go to original source... Go to PubMed...
  26. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869. Go to original source... Go to PubMed...
  27. Parving HH, Lehnert H, Brochner-Mortensen J, et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-878. Go to original source... Go to PubMed...
  28. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-2031. Go to original source... Go to PubMed...
  29. Van Zwieten P. Beneficial Combinations of two or more Antihypertensive Agents. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management. 2003; 4: 18.
  30. Malacco E, Santonastaso M, Vari N, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. Clin Ther. In press.
  31. Volpe M, Junren Z, Maxwell T, et al. Comparison of the blood pressure-lowering effects and tolerability of Losartan-and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther. 2003; 25: 1469-1489. Go to original source... Go to PubMed...
  32. Townsend R, Haggert B, Liss C, et al. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995; 17: 911-923. Go to original source... Go to PubMed...
  33. McInnes GT, O´Kane KP, Istad H, et al. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000; 14: 263-269. Go to original source... Go to PubMed...
  34. Conlin PR, Elkins M, Liss C, et al. A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension. J Hum Hypertens. 1998; 12: 693-699. Go to original source... Go to PubMed...
  35. Malacco E, Vari N, Capuano V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003; 25: 2765-2780. Go to original source... Go to PubMed...
  36. Franco RJ, Goldflus S, McQuitty M, et al. Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. Blood Press. 2003; 12: 41-47. Go to original source...
  37. Malacco E, Palatini P. Comparison of the effects of valsartan and amlodipine alone or combined with low-dose diuretic on ambulatory blood pressure in elderly patients with isolated systolic hypertension (Val-Syst Study)[abstract]. Eur Heart J. 2003; 24: 582. Go to original source...
  38. Flack JM, Saunders E, Gradman A, et al. Antihypertensive-efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001; 23: 1193-1208. Go to original source... Go to PubMed...
  39. Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens (Greenwich).2003; 5: 9-13. Go to original source... Go to PubMed...
  40. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583-592. Go to original source... Go to PubMed...
  41. Grundmann M, Kacířová I. The Mistakes in Combination Therapy of Resistant Hypertension. Basic Clin. Pharmacol. Toxicol. 2005; 97 (Suppl. 1): S64.
  42. Granger CB, Mc Murray JJV, Yusuf S, et all, fot the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet; 362: 772-776.
  43. Dahlöf B, Sever P S, Poulter N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, Sept. 4, 1-12. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.